Deutsche Bank AG Has $3.59 Million Stake in Indivior PLC (NASDAQ:INDV)

Deutsche Bank AG lifted its stake in shares of Indivior PLC (NASDAQ:INDV) by 14.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 288,473 shares of the company’s stock after buying an additional 35,953 shares during the quarter. Deutsche Bank AG owned about 0.21% of Indivior worth $3,586,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Deerfield Management Company L.P. Series C grew its position in shares of Indivior by 74.4% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 8,883,160 shares of the company’s stock worth $110,418,000 after buying an additional 3,790,518 shares during the period. Cubist Systematic Strategies LLC bought a new position in shares of Indivior in the 4th quarter worth $2,722,000. Balyasny Asset Management L.P. lifted its holdings in shares of Indivior by 142.5% in the 4th quarter. Balyasny Asset Management L.P. now owns 36,381 shares of the company’s stock worth $452,000 after purchasing an additional 21,379 shares in the last quarter. Alta Fundamental Advisers LLC lifted its holdings in shares of Indivior by 23.1% in the 4th quarter. Alta Fundamental Advisers LLC now owns 400,000 shares of the company’s stock worth $4,972,000 after purchasing an additional 75,000 shares in the last quarter. Finally, Ardsley Advisory Partners LP lifted its holdings in shares of Indivior by 11.0% in the 4th quarter. Ardsley Advisory Partners LP now owns 1,200,000 shares of the company’s stock worth $14,916,000 after purchasing an additional 119,050 shares in the last quarter. Institutional investors and hedge funds own 60.33% of the company’s stock.

Indivior Trading Down 2.1%

Shares of NASDAQ:INDV opened at $11.44 on Wednesday. The stock’s fifty day simple moving average is $10.18 and its two-hundred day simple moving average is $10.66. Indivior PLC has a 1-year low of $7.33 and a 1-year high of $18.59. The stock has a market cap of $1.58 billion, a PE ratio of -32.69 and a beta of 0.98.

Indivior (NASDAQ:INDV) last issued its quarterly earnings data on Thursday, April 24th. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.19. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. The business had revenue of $266.00 million for the quarter, compared to analysts’ expectations of $240.13 million. On average, sell-side analysts forecast that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Rodman & Renshaw assumed coverage on Indivior in a report on Tuesday, January 28th. They issued a “buy” rating and a $16.00 target price on the stock. Piper Sandler cut their target price on Indivior from $16.00 to $13.00 and set an “overweight” rating on the stock in a report on Thursday, March 6th. Finally, RODMAN&RENSHAW upgraded Indivior to a “strong-buy” rating in a report on Tuesday, January 28th.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.